乌鸦传媒視頻

<乌鸦传媒視頻 class="page-title">Meeting Coverage

ASCO Video Pearls: Lung Cancer

<乌鸦传媒視頻 class="page-description">Video Pearls from the American Society of Clinical Oncology
NSCLC Treatment in Older Patients: What Predicts Functional Resilience?

Age, performance status may not be the best tools to gauge treatment tolerance, says Joy Tang, MD

image
<乌鸦传媒視頻 class="section_title">Latest ASCO Video Pearls: Lung Cancer Meeting Coverage
Efti, Pembrolizumab Doublet Continues to Impress in Metastatic NSCLC

Combination safe and showed antitumor activity regardless of PD-L1 status

July 6, 2022
Comprehensive Molecular Genotyping Improves OS in Metastatic NSCLC

Charu Aggarwal, MD, says genotyping these patients is an important step toward precision medicine

June 29, 2022
Improving DFS in Lung Cancer Is an Acceptable Endpoint

Jorge Nieva counters Jack West: patients need options in adjuvant setting

June 28, 2021
IMpower010: Post-Op Atezolizumab Improves DFS in Lung Cancer

Jack West opens the debate about whether DFS endpoint is sufficient to change practice

June 21, 2021
<乌鸦传媒視頻 class="section_title"> Latest Oncology/Hematology Meeting Coverage